All Stories

Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial

Boehringer widens fibrosis drug's approval path after b...

Feb 10, 2025 0

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibr...

UPDATE: 22 states sue NIH over biomedical research grant cap designed to save $4B annually

UPDATE: 22 states sue NIH over biomedical research gran...

Feb 10, 2025 0

A new initiative rolled out under President Donald Trump’s administration is cut...

FDA amplifies BD atherectomy safety alert following 4 deaths

FDA amplifies BD atherectomy safety alert following 4 d...

Feb 10, 2025 0

According to the agency, BD has reported 30 serious injuries and four deaths lin...

NIH caps 'indirect costs' in biomedical research grants, aims to save $4B per year

NIH caps 'indirect costs' in biomedical research grants...

Feb 10, 2025 0

A new initiative rolled out under President Donald Trump’s administration is cut...

Globus Medical to buy neurostim developer Nevro for $250M

Globus Medical to buy neurostim developer Nevro for $250M

Feb 10, 2025 0

With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to...

Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial

Boehringer widens fibrosis drug’s approval path after b...

Feb 10, 2025 0

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibr...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH

Eli Lilly inks duo of deals, teaming with AdvanCell, Ol...

Feb 10, 2025 0

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and Ol...

Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger

Kineta sells Genentech and Merck deals to investor ahea...

Feb 10, 2025 0

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up ...

After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech

After phase 3 miss, Relmada picks up midstage Tourette'...

Feb 10, 2025 0

After sharing plans to shutter last summer, Asarina Pharma has managed to sell o...

Pliant pauses phase 2 lung fibrosis trial on advice of safety committee

Pliant pauses phase 2 lung fibrosis trial on advice of ...

Feb 10, 2025 0

Pliant Therapeutics has hit the breaks on a mid-stage trial of its lead liver di...

'Tough but necessary decisions': Frontier Medicines lays off staff to streamline operations

'Tough but necessary decisions': Frontier Medicines lay...

Feb 9, 2025 0

Precision medicines biotech Frontier Medicines is leaving behind an unknown numb...

UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update

UPDATED: Eli Lilly lops Alzheimer's and obesity assets ...

Feb 9, 2025 0

Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clin...

Viracta Therapeutics hits end of the line, laying off all workers and winding down

Viracta Therapeutics hits end of the line, laying off a...

Feb 9, 2025 0

Cancer biotech Viracta Therapeutics has closed its doors, laying off all employe...

Denali eyes approval after Hunter syndrome drug clears safety measures, reduces biomarkers in open-label study

Denali eyes approval after Hunter syndrome drug clears ...

Feb 9, 2025 0

After winning a breakthrough therapy designation for its Hunter syndrome enzyme ...

CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing

CF-focused Sionna goes public in $135M IPO, while Aardv...

Feb 9, 2025 0

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning w...

Cancer vaccine prevents recurrence of advanced kidney cancer in small trial

Cancer vaccine prevents recurrence of advanced kidney c...

Feb 9, 2025 0

After their advanced kidney tumors were surgically removed, nine patients were p...

Pfizer builds out oncology team with appointment of Novartis vet Jeff Legos

Pfizer builds out oncology team with appointment of Nov...

Feb 9, 2025 0

Pfizer is laying down new pieces for its leadership team structure, selecting Je...

Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect

Novo Nordisk adds pediatric data to bulging bag of evid...

Feb 9, 2025 0

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug cand...

Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach

Cullinan CEO talks autoimmune pivot, upcoming lupus rea...

Feb 9, 2025 0

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to ...

Fierce Biotech Layoff Tracker 2025: Viracta shuts down; Layoffs hit Frontier

Fierce Biotech Layoff Tracker 2025: Viracta shuts down;...

Feb 9, 2025 0

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year

Boston Scientific clocks over $1B in Farapulse revenue ...

Feb 9, 2025 0

That includes treating more than 200,000 patients with the irregular heartbeat k...

Glucotrack’s 3-year diabetes sensor implant clears initial human safety trial

Glucotrack’s 3-year diabetes sensor implant clears init...

Feb 9, 2025 0

Glucotrack has cleared the first human clinical study of its long-term continuou...

X4 lays off 30% of staff, halts preclinical R&D to focus on Xolremdi rollout

X4 lays off 30% of staff, halts preclinical R&D to focu...

Feb 9, 2025 0

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as...

AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug

AstraZeneca CEO defends 'fantastic' Alexion buyout in f...

Feb 9, 2025 0

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, tri...

6
7
8
9

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.